NEW YORK (GenomeWeb) - WaferGen Bio-systems reported after the close of the market on Tuesday that its second quarter revenues rose 56 percent, driven by an increase in product revenues.

For the three months ended June 30, the company reported revenues of $2.5 million, up from $1.6 million in the prior-year period. Product revenues accounted for all recorded revenues, rising 70 percent, primarily attributable to increases in sales of its SmartChip NGS target enrichment system. The firm did not record any license and royalty revenue in the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.